Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089657926> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W3089657926 endingPage "IA14" @default.
- W3089657926 startingPage "IA14" @default.
- W3089657926 abstract "Abstract Despite the ability to effectively achieve control of uveal melanoma at the site of origin, patient outcomes have remained suboptimal due to the ultimate development of recurrent distant disease in a significant proportion of those diagnosed, together with the limited efficacy of currently available therapies in this setting. Initial insights into the tumorigenic effects of the functionally activating, mutually exclusive, early event mutations in GNAQ, GNA11, PLCB4, and CYSLTR2 led to the development of a generation of trials evaluating the effects of inhibition of single or multiple downstream pathways including the MAPK and PI3K pathways. Given the dramatic efficacy of targeted therapy in cutaneous melanoma harboring a BRAF mutation, there was initial hope that a similar strategy might demonstrate comparable effects in uveal melanoma. Unfortunately, the completed and reported clinical trials targeting these pathways have demonstrated minimal, if any, efficacy. Likewise, despite the initial enthusiasm for immunologic checkpoint blockade for the treatment of metastatic uveal melanoma given the durable antitumor responses and cures achieved in cutaneous melanoma, the activity observed thus far has been limited. Nevertheless, with the critical and clinically significant advances made over that past 10 years in precision oncology and immuno-oncology, coupled with rapidly developing advances in our understanding of the biology of uveal melanoma, there is now a new cause for hope for our patients. Trials evaluating the inhibition of alternative nodes in activated pathways alone or in preclinically synergistic combinations are ongoing, new epigenetic strategies are being explored, and preliminary promising data from novel immunologic treatment strategies including adoptive cellular therapy and T-cell redirection all provide new optimism that these innovative treatment options may meaningfully impact the course of the disease. Citation Format: Richard D. Carvajal. Immunosensitivity and resistance in advanced uveal melanoma [abstract]. In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr IA14." @default.
- W3089657926 created "2020-10-08" @default.
- W3089657926 creator A5086473468 @default.
- W3089657926 date "2020-10-01" @default.
- W3089657926 modified "2023-10-02" @default.
- W3089657926 title "Abstract IA14: Immunosensitivity and resistance in advanced uveal melanoma" @default.
- W3089657926 doi "https://doi.org/10.1158/1538-7445.mel2019-ia14" @default.
- W3089657926 hasPublicationYear "2020" @default.
- W3089657926 type Work @default.
- W3089657926 sameAs 3089657926 @default.
- W3089657926 citedByCount "0" @default.
- W3089657926 crossrefType "journal-article" @default.
- W3089657926 hasAuthorship W3089657926A5086473468 @default.
- W3089657926 hasConcept C104317684 @default.
- W3089657926 hasConcept C121608353 @default.
- W3089657926 hasConcept C126322002 @default.
- W3089657926 hasConcept C143998085 @default.
- W3089657926 hasConcept C170493617 @default.
- W3089657926 hasConcept C2777658100 @default.
- W3089657926 hasConcept C2778468042 @default.
- W3089657926 hasConcept C2779134260 @default.
- W3089657926 hasConcept C2779176653 @default.
- W3089657926 hasConcept C2781230642 @default.
- W3089657926 hasConcept C501734568 @default.
- W3089657926 hasConcept C502942594 @default.
- W3089657926 hasConcept C535046627 @default.
- W3089657926 hasConcept C55493867 @default.
- W3089657926 hasConcept C71924100 @default.
- W3089657926 hasConcept C86803240 @default.
- W3089657926 hasConceptScore W3089657926C104317684 @default.
- W3089657926 hasConceptScore W3089657926C121608353 @default.
- W3089657926 hasConceptScore W3089657926C126322002 @default.
- W3089657926 hasConceptScore W3089657926C143998085 @default.
- W3089657926 hasConceptScore W3089657926C170493617 @default.
- W3089657926 hasConceptScore W3089657926C2777658100 @default.
- W3089657926 hasConceptScore W3089657926C2778468042 @default.
- W3089657926 hasConceptScore W3089657926C2779134260 @default.
- W3089657926 hasConceptScore W3089657926C2779176653 @default.
- W3089657926 hasConceptScore W3089657926C2781230642 @default.
- W3089657926 hasConceptScore W3089657926C501734568 @default.
- W3089657926 hasConceptScore W3089657926C502942594 @default.
- W3089657926 hasConceptScore W3089657926C535046627 @default.
- W3089657926 hasConceptScore W3089657926C55493867 @default.
- W3089657926 hasConceptScore W3089657926C71924100 @default.
- W3089657926 hasConceptScore W3089657926C86803240 @default.
- W3089657926 hasIssue "19_Supplement" @default.
- W3089657926 hasLocation W30896579261 @default.
- W3089657926 hasOpenAccess W3089657926 @default.
- W3089657926 hasPrimaryLocation W30896579261 @default.
- W3089657926 hasRelatedWork W1521649351 @default.
- W3089657926 hasRelatedWork W2118511673 @default.
- W3089657926 hasRelatedWork W2141202463 @default.
- W3089657926 hasRelatedWork W2774165137 @default.
- W3089657926 hasRelatedWork W2940291671 @default.
- W3089657926 hasRelatedWork W3089628014 @default.
- W3089657926 hasRelatedWork W3126366955 @default.
- W3089657926 hasRelatedWork W4362493042 @default.
- W3089657926 hasRelatedWork W4362493353 @default.
- W3089657926 hasRelatedWork W4362495258 @default.
- W3089657926 hasVolume "80" @default.
- W3089657926 isParatext "false" @default.
- W3089657926 isRetracted "false" @default.
- W3089657926 magId "3089657926" @default.
- W3089657926 workType "article" @default.